Skip to main content

Graphite Bio, Inc. (GRPH)

NASDAQ: GRPH · IEX Real-Time Price · USD
13.00
+0.22 (1.72%)
After-hours:Oct 15, 2021 6:49 PM EDT
12.78
0.05 (0.39%)
At close: Oct 15, 4:00 PM

Company Description

Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases.

Our next-generation gene editing platform allows us to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations.

We believe our approach could enable broad applications to transform human health, including directly correcting mutations, engineering cells to permanently deliver therapeutic proteins, and precisely engineering effector cells to treat or cure a wide range of serious genetic and other diseases, including cancer, autoimmune and neurodegenerative diseases.

Our lead product candidate GPH101 is a highly differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression.

We have received clearance of our Investigational New Drug (IND) and we intend to enroll the first patient in a Phase 1/2 clinical trial of GPH101 in the second half of 2021, with initial proof-of-concept data expected by the end of 2022.

We are also advancing our research programs and pipeline of potentially one-time curative therapies and intend to file an IND for a second program by mid 2023.

Graphite Bio, Inc.
CountryUnited States
Founded2019
IPO DateJun 25, 2021
IndustryBiotechnology
SectorHealthcare
Employees49
CEOJosh Lehrer, M.D.

Contact Details

Address:
279 East Grand Avenue, Suite 430
South San Francisco, CA 94080
United States
Phone650-484-0886
Websitegraphitebio.com

Stock Details

Ticker SymbolGRPH
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$17.00
CIK Code1815776
ISIN NumberUS38870X1046
Employer ID84-4867570

Key Executives

NamePosition
Dr. Joshua Lehrer-Graiwer FACC, M.D.President, Chief Executive Officer and Director
Dr. Matthew PorteusAcademic Founder and Director
Dr. Maria Grazia Roncarolo M.D., Ph.D.Academic Founder
Philip P. GutryChief Business Officer, Head of Finance and Investor Relations
Katherine Vega StultzChief Operating Officer
Dr. Daniel Dever Ph.D.Co-founder and Head of Translational Science
Jerry CaciaChief Technical Officer
Dr. Jane Grogan Ph.D.Chief Scientific Officer
Julia TranSenior Vice President of People